Skip to main content
September 28, 2009

Good clinical outcome after ischemic stroke with successful revascularization is time-dependent

September 29, 2009 issue
73 (13) 1066-1072


Background: Trials of IV recombinant tissue plasminogen activator (rt-PA) have demonstrated that longer times from ischemic stroke symptom onset to initiation of treatment are associated with progressively lower likelihoods of clinical benefit, and likely no benefit beyond 4.5 hours. How the timing of IV rt-PA initiation relates to timing of restoration of blood flow has been unclear. An understanding of the relationship between timing of angiographic reperfusion and clinical outcome is needed to establish time parameters for intraarterial (IA) therapies.
Methods: The Interventional Management of Stroke pilot trials tested combined IV/IA therapy for moderate-to-severe ischemic strokes within 3 hours from symptom onset. To isolate the effect of time to angiographic reperfusion on clinical outcome, we analyzed only middle cerebral artery and distal internal carotid artery occlusions with successful reperfusion (Thrombolysis in Cerebral Infarction 2–3) during the interventional procedure (<7 hours). Time to angiographic reperfusion was defined as time from stroke onset to procedure termination. Good clinical outcome was defined as modified Rankin Score 0–2 at 3 months.
Results: Among the 54 cases, only time to angiographic reperfusion and age independently predicted good clinical outcome after angiographic reperfusion. The probability of good clinical outcome decreased as time to angiographic reperfusion increased (unadjusted p = 0.02, adjusted p = 0.01) and approached that of cases without angiographic reperfusion within 7 hours.
Conclusions: We provide evidence that good clinical outcome following angiographically successful reperfusion is significantly time-dependent. At later times, angiographic reperfusion may be associated with a poor risk–benefit ratio in unselected patients.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (khari_73-13-1066.pdf)


Hacke W, Donnan G, Fieschi C, et al, ATLANTIS Trials Investigators, ECASS Trials Investigators, NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768–774.
Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000;55:1649–1655.
NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587.
Hacke W, Kaste M, Bluhmki E, et al, ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317–1329.
Wahlgren N, Ahmed N, Eriksson N, et al, for the SITS-MOST Investigators. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke–Monitoring Study (SITS-MOST). Stroke Epub 2008.
Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke: The PROACT II study: a randomized controlled trial: Prolyse in acute cerebral thromboembolism. JAMA 1999;282:2003–2011.
Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004;35:904–911.
IMS II Trial Investigators. The Interventional Management of Stroke (IMS) II Study. Stroke 2007;38:2127–2135.
Smith WS, Sung G, Starkman S, et al, MERCI Trial Investigators. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005;36:1432–1438.
Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007;38:967–973.
del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992;32:78–86.
Wolpert SM, Bruckmann H, Greenlee R, Wechsler L, Pessin MS, del Zoppo GJ. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator: The rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol 1993;14:3–13.
Molina CA, Alvarez-Sabin J, Montaner J, et al. Thrombolysis-related hemorrhagic infarction: a marker of early angiographic reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke 2002;33:1551–1556.
Khatri P, Wechsler LR, Broderick JP. ICH associated with revascularization therapies. Stroke 2007;38:431–440.
Smith WS. Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke: Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. AJNR Am J Neuroradiol 2006;27:1177–1182.
Jahan R. Hyperacute therapy of acute ischemic stroke: intraarterial thrombolysis and mechanical revascularization strategies. Tech Vas Interv Radiol 2005;8:87–91.
McDougall C, Clark W, Mayer T, et al. The Penumbra Stroke Trial: safety and effectiveness of a new generation of mechanical devices for clot removal in acute ischemic stroke. Presented at the International Stroke Conference, New Orleans, LA, 2008.
Higashida R, Furlan A, Roberts H, et al. Trial design and reporting standards for intraarterial cerebral thrombolysis for acute ischemic stroke. J Vasc Interv Radiol 2003;14:S493–S494.
Khatri P, Neff J, Broderick JP, Khoury JC, Carrozzella J, Tomsick T, IMS-I Investigators. Revascularization end points in stroke interventional trials: recanalization versus angiographic reperfusion in IMS-I. Stroke 2005;36:2400–2403.
Khatri P, Hill MD, Palesch YY, et al, for the IMS III Investigators. Methodology of the Interventional Management of Stroke (IMS) III Trial. Int J Stroke 2008;3:130–137.
Johnston KC, Connors AF Jr, Wagner DP, Haley EC Jr. Predicting outcome in ischemic stroke: external validation of predictive risk models. Stroke 2003;34:200–202.
Henon H, Godefroy O, Leys D, et al. Early predictors of death and disability after acute cerebral ischemic event. Stroke 1995;26:392–398.
Wechsler LR, Roberts R, Furlan AJ, et al, PROACT II Investigators. Factors influencing outcome and treatment effect in PROACT II. Stroke 2003;34:1224–1229.
König IR, Ziegler A, Bluhmki E, et al. Virtual International Stroke Trials Archive (VISTA) Investigators: predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke 2008;39:1821–1826.
Kissela B, Lindsell CJ, Kleindorfer D, et al. Clinical prediction of functional outcome after ischemic stroke: the surprising importance of periventricular white matter disease and race. Stroke 2009;40:530–536.
Savitz SI, Schlaug G, Caplan L, Selim M. Arterial occlusive lesions recanalize more frequently in women than in men after intravenous tissue plasminogen activator administration for acute stroke. Stroke 2005;36:1447–1451.
Ribo M, Alvarez-Sabin J, Montaner J, et al. Temporal profile of recanalization after intravenous tissue plasminogen activator: selecting patients for rescue angiographic reperfusion techniques. Stroke 2006;37:1000–1004.
Wunderlich MT, Goertler M, Postert T, et al, Duplex Sonography in Acute Stroke (DIAS) Study Group, Competence Network Stroke. Recanalization after intravenous thrombolysis: does a recanalization time window exist? Neurology 2007;68:1364–1368.
Molina CA, Montaner J, Abilleira S, et al. Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: a case-control study. Stroke 2001;32:2821–2827.
Christou I, Alexandrov AV, Burgin WS, et al. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial Doppler correlates with clinical recovery from ischemic stroke. Stroke 2000;31:1812–1816.
Bendszus M, Urbach H, Ries F, Solymosi L. Outcome after local intra-arterial fibrinolysis compared with the natural course of patients with a dense middle cerebral artery on early CT. Neuroradiol 1998;40:54–58.
Zaidat OO, Suarez JI, Sunshine JL, et al. Thrombolytic therapy of acute ischemic stroke: correlation of angiographic recanalization with clinical outcome. AJNR Am J Neuroradiol 2005;26:880–884.
Wechsler LR, Roberts R, Furlan AJ, et al. Factors influencing outcome and treatment effect in PROACT II. Stroke 2003;34:1224–1229.
Zivin JA. Factors determining the therapeutic window for stroke. Neurology 1998;50:599–603.
Pancioli AM, Brott TG. Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in acute ischemic stroke: scientific rationale and available evidence. CNS Drugs 2004;18:981–988.
Nallamothu BK, Bradley EH, Krumholz HM. Time to treatment in primary percutaneous coronary intervention. N Engl J Med 2007;357:1631–1638.
Neumann-Haefelin T, Steinmetz H. Time is brain: is MRI the clock? Curr Opin Neurol 2007;20:410–416.
Albers GW, Thijs VN, Wechsler L, et al, DEFUSE Investigators. Magnetic resonance imaging profiles predict clinical response to early angiographic reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006;60:508–517.
Davis SM, Donnan GA, Parsons MW, et al, EPITHET investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008;7:299–309.

Information & Authors


Published In

Volume 73Number 13September 29, 2009
Pages: 1066-1072
PubMed: 19786699

Publication History

Published online: September 28, 2009
Published in print: September 29, 2009


Request permissions for this article.



Affiliations & Disclosures

P. Khatri, MD
From the University of Cincinnati (P.K., T.A., C.N., J.P.B., T.A.T.), OH; and Medical University of South Carolina (S.D.Y.), Charleston.
T. Abruzzo, MD
From the University of Cincinnati (P.K., T.A., C.N., J.P.B., T.A.T.), OH; and Medical University of South Carolina (S.D.Y.), Charleston.
S. D. Yeatts, PhD
From the University of Cincinnati (P.K., T.A., C.N., J.P.B., T.A.T.), OH; and Medical University of South Carolina (S.D.Y.), Charleston.
C. Nichols, MD
From the University of Cincinnati (P.K., T.A., C.N., J.P.B., T.A.T.), OH; and Medical University of South Carolina (S.D.Y.), Charleston.
J. P. Broderick, MD
From the University of Cincinnati (P.K., T.A., C.N., J.P.B., T.A.T.), OH; and Medical University of South Carolina (S.D.Y.), Charleston.
T. A. Tomsick, MD
From the University of Cincinnati (P.K., T.A., C.N., J.P.B., T.A.T.), OH; and Medical University of South Carolina (S.D.Y.), Charleston.
For the IMS I and II Investigators
From the University of Cincinnati (P.K., T.A., C.N., J.P.B., T.A.T.), OH; and Medical University of South Carolina (S.D.Y.), Charleston.


Address correspondence and reprint requests to Dr. Pooja Khatri, Department of Neurology, University of Cincinnati Academic Health Center, 260 Stetson St., Ste 2308, PO Box 670525, Cincinnati, OH 45267-0525 [email protected]

Metrics & Citations



Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Basilar artery recanalization by proximal balloon occlusion and aspiration in a single vessel vertebrobasilar system: A case report, Brain Circulation, 9, 2, (103), (2023).
  2. Image Quality and Radiation Dose of Conventional and Wide-Field High-Resolution Cone-Beam Computed Tomography for Cerebral Angiography: A Phantom Study, Tomography, 9, 5, (1683-1693), (2023).
  3. Intra-arterial tenecteplase is safe and may improve the first-pass recanalization for acute ischemic stroke with large-artery atherosclerosis: the BRETIS-TNK trial, Frontiers in Neurology, 14, (2023).
  4. Recanalization Rate and Clinical Outcomes of Intravenous Tissue Plasminogen Activator Administration for Large Vessel Occlusion Stroke Patients, Journal of Korean Neurosurgical Society, 66, 2, (144-154), (2023).
  5. Advances in Futile Reperfusion following Endovascular Treatment in Acute Ischemic Stroke due to Large Vessel Occlusion, European Neurology, 86, 2, (95-106), (2023).
  6. Novel technique of stent placement via gateway balloon in intracranial atherosclerosis‐associated large vessel occlusion, Journal of Neuroimaging, 33, 5, (773-780), (2023).
  7. Thromboelastography as a predictor of functional outcome in acute ischemic stroke patients undergoing endovascular treatment, Thrombosis Research, 225, (95-100), (2023).
  8. Modeling the response of homogeneous and heterogeneous cerebral capillary networks to local changes in vessel diameters, Journal of Theoretical Biology, 568, (111509), (2023).
  9. Management of a recurrent stroke due to a carotid web, JMV-Journal de Médecine Vasculaire, 48, 3-4, (136-141), (2023).
  10. Reperfusion therapy in acute ischemic stroke, Journal of the Korean Medical Association, 65, 7, (430-439), (2022).
  11. See more

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to access the full text.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML







Share article link